In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects
This included Matthias Tschp (figure 39), a German who completed a medical degree at Ludwig Maximilian University of Munich in 1993 and then worked as a clinician in neuroendocrinology before taking up a research fellowship at Eli Lilly Discovery Research Laboratories in 1999 to gain expertise in drug discovery and development
Your healthcare provider and Medicare plan can help confirm whether your prescription should be covered through Part D or if you may be eligible for the Medicare GLP-1 Bridge program
Retain high-value clients, deliver life-changing results, and position yourself as a trusted leader in medical fitness
At the maximum 12 mg dose, 11.2% of participants discontinued due to adverse events
Weight loss at 24 weeks (primary endpoint): Weight loss at 48 weeks (secondary endpoint): The weight loss curves had not plateaued at 48 weeks
